Aduro Biotech Inc logo

ADRO - Aduro Biotech Inc Share Price

$1.4 0.1  4.5%

Last Trade - 17/01/20

Sector
Healthcare
Size
Small Cap
Market Cap £86.7m
Enterprise Value £-91.5m
Revenue £12.6m
Position in Universe 4210th / 6415
Bullish
Bearish
Unlock ADRO Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ADRO Revenue Unlock ADRO Revenue

Net Income

ADRO Net Income Unlock ADRO Revenue

Normalised EPS

ADRO Normalised EPS Unlock ADRO Revenue

PE Ratio Range

ADRO PE Ratio Range Unlock ADRO Revenue

Dividend Yield Range

ADRO Dividend Yield Range Unlock ADRO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ADRO EPS Forecasts Unlock ADRO Revenue
Profile Summary

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated May 5, 2011
Public Since April 15, 2015
No. of Shareholders: 115
No. of Employees: 152
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 80,514,459
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ADRO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ADRO
Upcoming Events for ADRO
Similar to ADRO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.